Amanta Healthcare Limited (AMANTA)

Loading page…

Amanta Healthcare Limited (AMANTA) · mywealthgrid

About

Amanta Healthcare Limited operates as a pharmaceutical manufacturer within India's healthcare sector. With a market capitalisation of ₹606.56 Cr, it competes at mid-cap scale. The company has shown quarterly revenues in the ₹65–₹77 Cr range over the past year, with consistent operating margins near 21%.

Face value: ₹10

Market cap

₹739 Cr

P/E

50.3×

P/B

3.4×

Dividend yield

ROE

6.8%

ROCE

10.7%

Debt / equity

1.06

OPM

20.8%

EPS (TTM)

₹3.8

Book value

₹56.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue swings from ₹68.8 Cr (Jun 2026) to ₹76.99 Cr (Mar 2026) within a quarter indicate demand variability; verify underlying drivers
Net profit volatility from ₹1.21 Cr (Sep 2025) to ₹5.53 Cr (Mar 2026) raises earnings quality concerns; verify cost structure stability
ROE of 6.76% substantially lags operating margin of 20.81%, suggesting capital efficiency challenges; verify asset utilisation and capital allocation
PE ratio of 41.32 is elevated; verify earnings growth expectations and identify sustainable growth catalysts

Generated analysis · source review pending

Growth drivers

YoY revenue growth of 5.3% (₹65.31 Cr Jun 2025 to ₹68.8 Cr Jun 2026) demonstrates organic momentum; verify if trajectory accelerates
Operating margin consistency at 20.81% OPM (range 19.42%–22.81%) indicates cost structure efficiency; revenue growth could drive faster profit expansion
Pharma sector growth in India from healthcare expansion; verify Amanta's positioning in high-growth therapeutic segments and market opportunity

Generated analysis · source review pending

260 historical price candles were omitted because the exchange source has not been verified.

₹190.4+2%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 20.8%
+High promoter holding of 63.8% with no pledge

Cons

−Low return on equity of 6.8% (3-yr avg)
−Profit declined 34.9% a year over the last 3 years
−Modest revenue growth of 8.5% a year over the last 3 years

Research score

Structured signal from quality, growth, valuation and momentum.

29/100

Business quality: 27
Growth: 17
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2026
	225	259	280	288
COGS	77	102	105	97
Gross profit	149	157	175	191
	34	51	64	131
	115	106	111	60
OPM %	50.9%	41.1%	39.5%	20.8%
Depreciation	17	18	20	19
Interest	44	35	34	21
	-68	4	1	1
Profit before tax	62	3	5	21
Tax	8	5	2	6
Tax %	12.8%	178.4%	32.7%	29.6%
	54	-2	4	15
PAT margin %	23.9%	-0.8%	1.3%	5.2%
EPS (₹)	—	—	—	4.3
EPS adjusted (₹)	—	—	—	3.8

₹ Cr	Mar 2026
Equity capital	39
Reserves	181
	234
	103
Total equity & liabilities	558
	198
CWIP	82
Investments	16
	261
Total assets	558

₹ Cr	Mar 2026
	48
	-94
	126
Net cash flow	81
Free cash flow	-32
CFO / Operating profit %	80.9%

Compounded sales growth

7 years: —
5 years: —
3 years: 9%
1 year: 3%

Compounded profit growth

7 years: —
5 years: —
3 years: -35%
1 year: 311%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 7%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2026
Margins
Gross margin %	65.9%	60.7%	62.5%	66.4%
EBITDA margin %	50.9%	41.1%	39.5%	20.8%
EBIT margin %	43.3%	34%	32.5%	14.3%
PAT margin %	23.9%	-0.8%	1.3%	5.2%
Working capital
Receivable days	—	—	—	55
Inventory days	—	—	—	312
Payable days	—	—	—	136
NWC days	—	—	—	231
Leverage
Current ratio	—	—	—	1.69
Debt to EBITDA	—	—	—	3.92
Debt to equity	—	—	—	1.06
Interest coverage	2.2	2.6	2.7	2.1
Asset turnover	—	—	—	0.52
Return ratios
Return on assets %	—	—	—	2.7%
Return on capital employed %	—	—	—	10.7%
Return on equity %	—	—	—	6.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	63.56%	63.56%	63.56%	63.72%	63.8%
	2.21%	1%	1.1%	0.85%	0.43%
	12.22%	11.34%	11.24%	12.88%	12.92%
Government	0%	0%	0%	0%	0%
	22.01%	24.1%	24.1%	22.55%	22.85%
No. of shareholders	—	18,669	16,181	15,222	12,612

Promoter holding up 0.24 percentage points since Jun 2025.

18 deals · 9 Sept 2025 – 11 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	3,80,749	₹156.24	₹5.95 Cr
11 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	3,80,749	₹156.07	₹5.94 Cr
11 Jun 2026	SILVERLEAF CAPITAL SERVICES PRIVATE LIMITED	Bulk	NSE	Buy	2,62,235	₹159.04	₹4.17 Cr
11 Jun 2026	SILVERLEAF CAPITAL SERVICES PRIVATE LIMITED	Bulk	NSE	Sell	2,62,235	₹158.85	₹4.17 Cr
11 Jun 2026	ALPHAGREP SECURITIES PRIVATE LIMITED	Bulk	NSE	Buy	2,18,854	₹156.56	₹3.43 Cr
11 Jun 2026	ALPHAGREP SECURITIES PRIVATE LIMITED	Bulk	NSE	Sell	2,18,854	₹156.35	₹3.42 Cr
11 Jun 2026	BLITZQUANT RESEARCH LLP	Bulk	NSE	Sell	2,05,983	₹158.96	₹3.27 Cr
11 Jun 2026	BLITZQUANT RESEARCH LLP	Bulk	NSE	Buy	2,05,983	₹158.85	₹3.27 Cr
16 Apr 2026	MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	Bulk	NSE	Buy	2,16,504	₹123.09	₹2.66 Cr
16 Apr 2026	MANSI SHARE AND STOCK BROKING PRIVATE LIMITED	Bulk	NSE	Sell	2,16,504	₹124.86	₹2.70 Cr

1–10 of 18

1 / 2

Mr. Bhavesh Girishbhai PatelExecutive Director-Chairperson related to Promoter-MD
Mr. Nimesh P PatelNon-Executive - Non Independent Director
Mr. Kshitij Manubhai PatelNon-Executive - Independent Director
Mrs. Anjali Nirav ChoksiNon-Executive - Independent Director
Mr. Nitin JainNon-Executive - Independent Director
Mr. Pratik Punamchand GandhiNon-Executive - Non Independent Director
Nikhita DinodiaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Amanta Healthcare Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results5 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

23 announcementsExport CSV

1 Oct 2026, 11:56 amCompany Update

Submission Of Disclosures Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Off Market Transfer Of Equity Shares

General PDF

1 Oct 2026, 10:33 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

30 Sept 2026, 4:55 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

30 Sept 2026, 12:21 pmCompany Update

Submission Of Disclosures Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Off Market Transfer Of Equity Shares

General PDF

16 Sept 2026, 7:51 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

16 Sept 2026, 7:02 pmAGM/EGM

Shareholder Meeting - Scrutinizer''''s Report

AGM PDF

16 Sept 2026, 6:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

16 Sept 2026, 4:33 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Date	Category	Subject	Filing
1 Oct 2026, 11:56 am	Company Update General	Submission Of Disclosures Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Off Market Transfer Of Equity Shares	PDF
1 Oct 2026, 10:33 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Loading announcements…

Amanta Healthcare Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Offer and rights documents

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Amanta Healthcare Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Offer and rights documents

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1